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However, centres prescribing complete, intermediate and incom-
plete work-ups were differently represented for the two diagnoses.
No statistically significant change emerged in diagnosis, diagnostic
confidence or clinical management between complete, intermedi-
ate or incomplete assessments (Table). Stratifying patients for etio-
pathology (AD-FTD) or clinical severity (MCI-dementia) led to the
same results. Conclusions:Collection of additional core bio-markers
does not seem to affect the incremental value of amyloid-PET in natu-
ralistic clinical setting. The clinicians combinations and use of instru-
mental examination needs to be better understood and elucidated in
view of the definition of an evidence-based diagnostic algorithm.
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Background:Changes in Alzheimer’s disease (AD) biomarkers can
be detected before cognitive decline using neuroimaging and CSF
measures. In autosomal dominant AD (ADAD), PET imaging bio-
markers of amyloidosis and hypometabolism (measured with Pitts-
burgh compound B [PiB] and fluorodeoxyglucose [FDG],
respectively) are detectable 15 and 10 years before any symptoms
develop. A new marker of neurodegeneration, increased CSF visi-
nin-like protein 1 (VILIP-1), may predict cognitive decline and has
been shown to be increased in carriers of an ADAD mutation. We
wanted to further characterize in ADAD this new marker of neuro-
degeneration by evaluating its relationship with well-known AD
biomarkers, in particular FDG hypometabolism, which is believed
to reflect neuronal dysfunction and injury. Methods: Participants
from the Dominantly Inherited Alzheimer Network (DIAN) study
(n¼202, including 124 mutation carriers [MC], 43 of whom were
symptomatic) underwent MRI, PiB and FDG PET scans and CSF
VILIP-1 measurement. Dementia severity was defined by the Clin-
ical Dementia Rating (CDR). The cohort was divided by mutation
status (non-carriers [NC] vs. MC) and b-amyloid status (PiB-nega-
tive vs. PiB-positive) for group comparisons. The standardized up-
take value ratio (SUVR) of PiB and FDG, obtained from an MRI-
based PET processing method, were corrected and normalized to
the brainstem. Partial correlations between PET SUVR data and
CSF-VILIP-1 levels controlling for age and family history were
performed. Results: This study confirmed increased CSF VILIP-1
levels and decreased FDG SUVR values in MC compared to NC.
Among carriers, PiB-positive participants had higher VILIP-1
levels compared to PiB-negative (p<0.005). VILIP-1 trended
higher in PiB-positive asymptomatic participants compared to
PiB-negative (p¼0.07). A positive correlation between mean
cortical PiB SUVR and VILIP-1 (r¼0.36, p<0.0001) and a nega-
tive correlation between FDG PET in the precuneus and VILIP-1
in all participants (r¼-0.33, p<0.0001) were observed. The nega-
tive correlation between CSF-VILIP-1 and FDG PET was driven
by the PiB-positve MC participants. Conclusions:These preliminary
results show that increased CSF VILIP-1, a marker of neuronal
injury, is associated with both abnormal amyloid deposition and
cerebral glucose hypometabolism in the DIAN population. Longi-
tudinal investigation and evaluation of other AD features are still
needed. Support: NIH/NIA U01AG032438.
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Background:Cerebral accumulation of b-amyloid (Ab) is thought to
be the starting mechanism in Alzheimer’s disease (AD).
Podium Presentations: Monday, July 25, 2016P246
